β1-adrenoreceptor antibody measurement and antibody removal effects on left ventricular contractility in dilated cardiomyopathy patients
Abstract
Aim. To develop a test system measuring β1-adrenoreceptor antibody (anti- β1-AR) level. To study the effects of autoantibody removal on left ventricular (LV) contractility.
Material and methods. Peptides, according to second human extracellular β1-AR loop fragments (197-222 amino acid fragments), were synthesized by modified hard-phase method and then lyophilized. Molecular mass control was performed by laser desorption mass spectrometry. In total, 47 patients were examined, with the aim of anti- β1-AR detection. Dilated cardiomyopathy (DCMP) was diagnosed in 22 patients, ischemic CMP – in 8, post-infarction cardiosclerosis – in 6, myocarditis – in 3, alcohol CMP – in 1, and post-transplantation CMP – in 7 participants. Anti- β1-AR were removed in 4 DCMP patients, by plasmapheresis (PF; n=3) or immunoadsorption (IA; n=1).
Results. A new immune-enzyme test system for autoantibody detection has been developed, using the second extracellular β1-AR loop 26 amino acid peptide as the antigen. Anti- β1-AR removal by IA or PF methods resulted in improved LV contractility among DCMP patients.
Conclusion. It is important to determine whether LV contractility improvement is explained by anti-β1-AR removal exclusively. More advanced methods for anti- β1-AR and other anti-myocardial antibody detection should be developed, and auto-antibodies’ role in impaired myocardial contractility should be studied.
About the Authors
E. A. Tabakyan
A.L. Myasnikov Research Institute of Clinical Cardiology, Russian Cardiology Scientific and Clinical Complex, State Federal Agency for Health and Social Development, Moscow
Russian Federation
Russian Federation
A. G. Tonevitsky
Research Institute of Transplantology and Artificial Organs, State Federal Agency for Health and Social Development
Russian Federation
Russian Federation
D. M. Ataullakhanova
A.L. Myasnikov Research Institute of Clinical Cardiology, Russian Cardiology Scientific and Clinical Complex, State Federal Agency for Health and Social Development, Moscow
Russian Federation
Russian Federation
A. Yu. Zaruba
A.L. Myasnikov Research Institute of Clinical Cardiology, Russian Cardiology Scientific and Clinical Complex, State Federal Agency for Health and Social Development, Moscow
Russian Federation
Russian Federation
V. V. Kukharchuk
A.L. Myasnikov Research Institute of Clinical Cardiology, Russian Cardiology Scientific and Clinical Complex, State Federal Agency for Health and Social Development, Moscow
Russian Federation
Russian Federation
References
1. Grogan M, Redfoeld MM, Bailey KR, et al. Long-term outcome of patients with biopsy-proved myocarditis: comparison with idiopathic dilated cardiomyopathy. JACC 1995; 26(1): 80-4.
2. Erdmann E. Tne management of the heart failure – an overview. Basic Res Cardiol 2000; 95: 13-7.
3. Freedman NJ, Lefkowitz RJ. Anti-β1-adrenergic receptor antibod- ies and heart failure: causation, not just correlation. J Clin Invest 2004; 113: 1379-82.
4. Шумаков В.И., Рулева Н.Ю., Коробов Н.В. и др. Разработка аналитического метода на основе иммуноферментного анализа для определения аутоантител к β1-адренорецепторам в сыворотке крови больных с дилатационной кардиомиопатией. Вест трансплант искусст орг 1999; 34-41.
5. Caforio AL, Goldman JH, Baig MK, et al. Cardiac autoantibodies in dilated cardiomyophathy become unedetectable with disease progression. Heart 1997; 77: 62-7.
6. Tomaszewski M, Brain NJ, Charchar FJ, et al. Essential Hypertension and β2-Adrenergic Receptor Gene. Hypertension 2002; 40: 286-91.
7. Lohse MJ, Engelhardt S, Eschenhagen, T. What ist he role of β-adrenergic signaling in heart failure? Circ Res 2003; 93: 896-906.
8. Lader AS, Xiao YF, Ishikawa Y, et al. Cardiac Gsα overexpression enhances L-type calcium channels through an adenylyl cyclase independent pathway. Proc Natl Acad Sci USA 1998; 95: 9669-74.
9. Matsui S, Fu ML, Hoebeke JJ. Peptides derived from cardiovascular G-protein-coupled receptors induce morphological cardiomyopatic changes in immunized rabbits. Mol Cell Cardiol 1977; 29: 641-55.
10. Jahns R, Вoivin V, Hein L, et al. Direct evidence for a β1-adrenergic receptor–directed autoimmune attack as a cause of idiopathic dilated cardiomyopathy. J Clin Invest 2004; 113: 1419-29.
11. Knebel F, Bohm M, Staudt A, et al. Reduction of morbidity by immunoadsorbtion therapy in patients with dilated cardiomyopathy. Int J Cardiol 2004; 97(3): 517-20.
12. Felix SB, Staudt A, Dorffel WD, et al. Hemodynamic Effects of Immunoadsorbtion and Subsequent Immunoglobulin Substitution in Dilated Cardiomyopathy. Three-Month from a Randomized Study. JACC 2000; 35(6): 1590-8.
13. Wisdom G.V. Peptide Antigens. Oxford University Press Inc. Oxford New York Tokyo 1994; 252.
14. Fraser CM. Site-directed mutagenesis of β-adrenergic receptors. J Biol Chem 1989; 264: 9266-70.
15. Strader CD, Candelore MR, Hill WS, et al. Identification of two serine residues involved in agonist activation of the β-adrenergic receptor. J Biol Chem 1989; 264: 13572-80.
16. Tota MR, Candelore MR, Dixon RAF, Strader CD. Biophysical and genetic analysis of the ligand binding site of the beta-adrenoceptor. Trends Pharmacol Sci 1991; 12: 4-6.
17. Naparstek Y, Plotz PH. The role of autoantibodies in autoimmune disease. Annu Rev Immunol 1993; 11: 79-104.
18. Kaplan D, Ferrari I, Bergami PL, et al. Antibodies to ribosomal P proteins of Tripanosoma cruzi in Chagas disease possess functional autoreactivity with heart tissue and differ from anti-P autoantibodies in lupus. Proc Natl Acad Sci USA 1997; 94: 10301-6.
Review
For citations:
Tabakyan E.A., Tonevitsky A.G., Ataullakhanova D.M., Zaruba A.Yu., Kukharchuk V.V. β1-adrenoreceptor antibody measurement and antibody removal effects on left ventricular contractility in dilated cardiomyopathy patients. Cardiovascular Therapy and Prevention. 2007;6(3):25-32. (In Russ.)
Views:
384
Email this article 
